Management of colorectal cancer

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Stintzing, Sebastian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CETUXIMAB; K RAS PROTEIN; PANITUMUMAB; REGORAFENIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; EXON; HUMAN; MICROSATELLITE INSTABILITY; PHYSICIAN; RECTUM CANCER;

EID: 84912045160     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-108     Document Type: Article

References (82)

1. Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. National Cancer Institute: Genetics of Colorectal Cancer (PDQ®). [http://www.cancer.gov/cancertopics/pdq/genetics/colorectal/HealthProfessional]
3. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004, 96:1420-5.
4. Campos FG, Logullo Waitzberg, AG, Kiss DR, Waitzberg DL, Habr-Gama A, Gama-Rodrigues J: Diet and colorectal cancer: current evidence for etiology and prevention. Nutr Hosp 2005, 20:18-25.
5. Doyle VC: Nutrition and colorectal cancer risk: a literature review. Gastroenterol Nurs 2007, 30:178-82; quiz 182-3.
6. Harriss DJ, Atkinson G, Batterham A, George K, Cable NT, Reilly T, Haboubi N, Renehan AG: Lifestyle factors and colorectal cancer risk (2): a systematic review and meta-analysis of associations with leisure-time physical activity. Colorectal Dis 2009, 11:689-701.
7. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D: The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007, 146:365-75.
8. Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007, 146:376-89.
9. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey J, Nagorney DM, McWilliams RR: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009, 27:3677-83.
10. Day DW, Morson BC: The adenoma-carcinoma sequence. Major Probl Pathol 1978, 10:58-71.
11. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525-32.
12. Ilyas M, Straub J, Tomlinson IP, Bodmer WF: Genetic pathways in colorectal and other cancers. Eur J Cancer 1999, 35:1986-2002.
13. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999, 96:8681-6.
14. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-12.
15. Noffsinger AE: Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol 2009, 4:343-64.
16. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson James KV, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV Krishna, et al.: The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-13.
17. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-7.
18. Dienstmann R, Guinney J, Delorenzi M, De Reynies A, Roepman P, Sadanandam A, Vermeulen L, Schlicker A, Missiaglia E, Soneson C, Marisa L, Homicsko K, Wang X, Simon I, Laurent-Puig P, Wessels LFA, Medema JP, Kopetz S, Friend SH, Tejpar S: Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus ofmolecular subtypes [abstract]. Presented at 2014 ASCO Annual Meeting: 30 May-3 June 2014; Chicago, IL.
19. Nagtegaal ID, Quirke P: What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008, 26:303-12.
20. Schmiegel W, Pox C, Adler G, Fleig W, Fölsch UR, Frühmorgen P, Graeven U, Hohenberger W, Holstege A, Junginger T, Kühlbacher T, Porschen R, Propping P, Riemann JF, Sauer R, Sauerbruch T, Schmoll HJ, Zeitz M, Selbmann HK: S3-Leitlinienkonferenz "Kolorektales Karzinom" 2004. Z Gastroenterol 2004, 42:1129-77.
21. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens J, Liersch T, Schmidberger H, Raab R: Preoperative versus postoperative chemoradiotherapy for rectal cancer. NEngl J Med 2004, 351:1731-40.
22. Hofheinz R, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012, 13:579-88.
23. Allegra CJ, Yothers Y, O'Connell MJ, Roh MS, Lopa SH, Petrelli NJ, Beart RW, Sharif S, Wolmark N: Final results from NSABP protocol R-04: Neoadjuvant chemoradiation (RT) comparing continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in patients with stage II and III rectal cancer [abstract]. Presented at 2014 ASCO Annual Meeting: 30 May-3 June 2014; Chicago, IL.
24. Peeters Koen CMJ, Marijnen Corrie AM, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius B, Leer JW, van de Velde, Cornelis JH: The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007, 246:693-701.
25. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, Metz C de, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M: Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009, 373:811-20.
26. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab H, Villanueva M, Witzigmann H, Wittekind C, Beissbarth T, Rödel C: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012, 30:1926-33.
27. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab H, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012, 13:679-87.
28. Rodel C, Liersch T, Fietkau R, Hohenberger W, Graeven U, Hothorn T, Arnold D, Raab H, Wittekind C, Hess CF, Staib L, Becker H, Sauer R: Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial [abstract]. Presented at 2014 ASCO Annual Meeting: 30 May-3 June 2014; Chicago, IL.
29. Schmoll H, Haustermans K, Price TJ, Nordlinger B, Hofheinz R, Daisne J, Janssens J, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth FWB, Hannig C, Zalcberg JR, Tebbutt NC, Mauer ME, Messina CGM, Lutz MP, Van Cutsem E: Preoperative chemoradiotherapy and postoperative chemotherapywith capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis [abstract]. Presented at 2014 ASCO Annual Meeting: 30 May-3 June 2014; Chicago, IL.
30. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L: Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011, 29:2773-80.
31. Gérard J, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne P, Vendrely V, François E, de La Roche Guy, Bouché O, Mirabel X, Denis B, Mineur L, Berdah J, Mahé M, Bécouarn Y, Dupuis O, Lledo G, Seitz J, Bedenne L, Juzyna B, Conroy T: Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012, 30:4558-65.
32. Hong YS, Nam B, Kim K, Lee J, Park JO, Park YS, Kim SY, Kim T, Kim JH, Ahn JB, Jung KH, Kim TW: Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy: Updated results of 3-year disease-free survival from a randomized phase II study (TheADORE) [Abstract]. Presented at 2014 ASCO Annual Meeting: 30 May-3 June 2014; Chicago, IL.
33. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-9.
34. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz J, Sinicrope F, Gallinger S: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010, 28:3219-26.
35. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010, 28:3937-44.
36. Jiang Y, Casey G, Lavery IC, Zhang Y, Talantov D, Martin-McGreevy M, Skacel M, Manilich E, Mazumder A, Atkins D, Delaney CP, Wang Y: Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn 2008, 10:346-54.
37. Oh SC, Park Y, Park ES, Lim JY, Kim SM, Kim S, Kim J, Kim SC, Chu I, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee J: Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 2012, 61:1291-8.
38. Kennedy RD, Bylesjo M, Kerr P, Davison T, Black JM, Kay EW, Holt RJ, Proutski V, Ahdesmaki M, Farztdinov V, Goffard N, Hey P, McDyer F, Mulligan K, Mussen J, O'Brien E, Oliver G, Walker SM, Mulligan JM, Wilson C, Winter A, O'Donoghue D, Mulcahy H, O'Sullivan J, Sheahan K, Hyland J, Dhir R, Bathe OF, Winqvist O, Manne U, et al.: Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol 2011, 29:4620-6.
39. Haller DG, Tabernero J, Maroun J, Braud F de, Price T, van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll H: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011, 29:1465-71.
40. André T, Boni C, Mounedji-Boudiaf L, NavarroM, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, Gramont A de: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl JMed 2004, 350:2343-51.
41. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198-204.
42. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345:1091-7.
43. McCleary NJ, Meyerhardt JA, Green E, Yothers G, Gramont A de, van Cutsem E, O'Connell M, Twelves CJ, Saltz LB, Haller DG, Sargent DJ: Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2013, 31:2600-6.
44. Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989, 7:1419-26.
45. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, Gramont A de: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-37.
46. van Cutsem E, Köhne C, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-9.
47. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T, Rivera F, Couture F, Sirzén F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy inmetastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-9.
48. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Koc?ova I, Ruff P, B?asińska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R: Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014, 25:1346-55.
49. Heinemann V, von Weikersthal, Ludwig Fischer, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes H, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014, 15:1065-75.
50. Venook AP, Niedzwiecki D, Lenz H, Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD: CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) [Abstract]. Presented at 2014 ASCO Annual Meeting: 30 May-3 June 2014; Chicago, IL.
51. Joulain F, Proskorovsky I, Allegra C, Tabernero J, Hoyle M, Iqbal SU, van Cutsem E: Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treatedmetastatic colorectal cancer. Br J Cancer 2013, 109:1735-43.
52. Falcone A, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Trenta P, Tomasello G, Ronzoni M, Ciuffreda L, Zaniboni A, Tonini G, Buonadonna A, Valsuani C, Chiara S, Carlomagno C, Boni C, Marcucci L, Boni L, Loupakis L: FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group [Abstract]. Presented at 2013 ASCO Annual Meeting: 31 May-4 June 2013; Chicago, IL.
53. Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi C, Antoniotti C, Bergamo F, Lonardi S, Zagonel V, Simi P, Fontanini G, Falcone A: FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014, 50:57-63.
54. Stintzing S, Jung A, Rossius L, Modest DP, von Weikersthal LF, Decker T, Kiani A, Al-Batran S, Vehling-Kaiser U, Heintges T, Moehler M, Scheithauer W, Kirchner T, Heinemann V: Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3-A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wildtype (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients [Abstract]. Presented at 2014 Gastrointestinal Cancers Symposium: 16-18 June 2014; San Francisco, CA.
55. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-7.
56. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-14.
57. Gramont A de, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, Braud F de, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as firstline treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-47.
58. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in firstline metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-705.
59. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel, Guy A, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ: Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010, 28:3191-8.
60. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP: Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013, 14:1077-85.
61. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, Braud F de, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-71.
62. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-42.
63. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007, 25:3238-45.
64. Ciardiello F, Lenz H, Kohne C, Heinemann V, Tejpar S, Melezinek I, Beier F, Stroh C, Van Cutsem E: Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab [Abstract]. Presented at 2014 ASCO Annual Meeting: 30 May-3 June 2014; Chicago, IL.
65. Douillard J, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, B?asińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013, 369:1023-34.
66. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon J, Hecht JR, Yu H, Oliner KS, Go WY: PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. J Clin Oncol 2014, 32:2240-7.
67. Bokemeyer C, Kohne C, Ciardiello F, Lenz H, Heinemann V, Klinkhardt U, Beier F, Duecker K, Tejpar S: Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab [Abstract]. Presented at 2014 ASCO Annual Meeting: 30 May-3 June 2014; Chicago, IL.
68. Fuchs CS, Marshall J, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008, 26:689-90.
69. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S, Heintges T, Lerchenmueller J, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Schaefer B, Modest DP, Jung A, Stintzing S: Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3) [Abstract]. Presented at 2013 ASCO Annual Meeting: 31 May-4 June 2013; Chicago, IL.
70. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon J, Hecht JR, Yu H, Oliner KS, Go WY: PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. J Clin Oncol 2014, 32:2240-7.
71. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, Gramont A de: Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009, 27:5727-33.
72. Arnold D, Graeven U, Lerchenmuller CA, Killing B, Depenbusch R, Steffens C, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Schmoll H, Reinacher-Schick A, Hegewisch-Becker S: Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207) [Abstract]. Presented at 2014 ASCO Annual Meeting: 30 May-3 June 2014; Chicago, IL.
73. Koopman M, Simkens LHJ, Tije AJT, Creemers G, Loosveld OJL, de Jongh FE, Erdkamp F, Erjavec Z, van der Torren AME, Van der Hoeven JJM, Nieboer P, Braun JJ, Jansen RL, Haasjes JG, Cats A, Wals JJ, Mol L, Dalesio O, van Tinteren H, Punt CJA: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG) [Abstract]. Presented at 2013 ASCO Annual Meeting: 31 May-4 June 2013; Chicago, IL.
74. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-44.
75. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, van Cutsem E, Moos R von, Viéitez JM, Bouché O, Borg C, Steffens C, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013, 14:29-37.
76. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJA, Strickland AH, Wilson G, Ciuleanu TE, Roman L, van Cutsem E, Tian Y, Sidhu R: Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014, 25:107-16.
77. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz H, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2311-9.
78. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracilresistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013, 14:749-59.
79. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-45.
80. van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon J, van Laethem J, Maurel J, Richardson G, Wolf M, Amado RG: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-64.
81. Grothey A, van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:303-12.
82. Yoshino T, Mayer R, Falcone A, Ohtsu A, Garcia-Carbonero R, Mizunuma A, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni, A, Hochster H, Benedetti F, Aivado M, Makris L, Ito M, Van Cutsem E: Results of a multicenter, randomized, double.-blind, phase III study of TAS-102 vs. placebo, with best supportive care (BSC), in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (RECOURSE). Ann Oncol 2014, 25(suppl 2):ii114.